3
Disclosures
Feb 4, 2026 — Apr 6, 2026
Date Range
STANDARD
Market Segment
Pharmaceutical
Sector

Disclosures

DateTypeHeadlinePDF
Apr 6 Other Wakamoto Pharmaceutical to Report Investment Securities Sale Gain of 152 million PDF
Feb 26 Admin WAKAMOTO PHARMACEUTICAL CO.,LTD. Announces Change of Representative Director PDF
Feb 4 Earnings Wakamoto Pharmaceutical Co., Ltd. Reports Q3 Revenue of 7.31 billion, Up 26% PDF

Disclosure Types

Other: 1 Admin: 1 Earnings: 1